1'-Acetylindirubin

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1'-Acetylindirubin
• 英文别名: 1-acetyl-1H,1'H-[2,3']biindolylidene-3,2'-dione；(2Z)-1-acetyl-2-(2-oxo-1H-indol-3-ylidene)indol-3-one
• 化学式: C₁₈H₁₂N₂O₃
• 分子量: 304.305
• InChiKey: BWCDBDQTFLQAGD-NXVVXOECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  66.48
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  吲哚乙酸酯 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 10.0h， 生成 1'-Acetylindirubin
  参考文献：
  名称：

  Synthesis and structure–activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities

  摘要：

  Indirubin, an active ingredient of a traditional Chinese recipe Danggui Loughui Wan, has been known as it CDK inhibitor competing with ATP for binding to the catalytic site of cyclin-dependent kinases (CDKs). Since CDKs, a group of serine/ threonine kinases forming active heterodimeric complexes with cyclins, are key regulators of the cell cycle regulation, therapeutic interventions targeting CDKs have been stimulated for the treatment of proliferative diseases, such as cancer, psoriasis, and for the prevention of chemotherapy-associated side effects, Such its alopecia. A series of novel indirubin analogs was synthesized and evaluated for anti-proliferative and CDK2 inhibitory activities. Among the indirubin derivatives tested in the growth inhibitions against several human cancer cell lines, 5-nitro, halide, and bulky group Containing acylamino Substituted analogs showed high anti-proliferative effects. Selected analogs showing potent anti-proliferative activities were evaluated further in the CDK2 enzyme assay, Which resulted in the discovery of potent CDK2 inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.08.008

文献信息

• [EN] INDIRUBIN DERIVATIVES HAVING ANTICANCER PROPERTY AGAINST HUMAN CANCER CELL ME<br/>[FR] DERIVES D'INDIRUBINE POSSEDANT UNE PROPRIETE ANTI-CANCER CONTRE LA LIGNEE CELLULAIRE DU CANCER HUMAIN
  申请人：ANYGEN CO LTD

  公开号：WO2005070416A1

  公开（公告）日：2005-08-04

  The present invention relates to an indirubin derivative having anticancer property by inhibiting cell proliferation as to human cancer cell line. More particularly, this invention provides the synthesis of indirubin derivative known as CDK(Cyclin-dependent kinase) inhibitor. Further, inhibition activity of proliferation as to human cancer cell line and apoptosis against induced-differentiation of said indirubin derivative are researched to develop a novel indirubin derivative having efficacious anticancer properties as to various human cell lines.

  本发明涉及一种通过抑制细胞增殖具有抗癌性能的靛蓝衍生物，针对人类癌细胞系。更具体地，该发明提供了一种被称为CDK（细胞周期依赖性激酶）抑制剂的靛蓝衍生物的合成。此外，针对人类癌细胞系的增殖抑制活性和对所述靛蓝衍生物诱导分化的细胞凋亡进行了研究，以开发一种具有有效抗癌性能的新型靛蓝衍生物，适用于各种人类细胞系。
• Indirubin derivatives having anticancer property against human cancer cell line
  申请人：Kim Yong-Chul

  公开号：US20070155816A1

  公开（公告）日：2007-07-05

  The present invention relates to an indirubin derivative having anticancer property by inhibiting cell proliferation as to human cancer cell line. More particularly, this invention provides the synthesis of indirubin derivative known as CDK(Cyclin-dependent kinase) inhibitor. Further, inhibition activity of proliferation as to human cancer cell line and apoptosis against induced-differentiation of said indirubin derivative are researched to develop a novel indirubin derivative having efficacious anticancer properties as to various human cell lines.
• US7572923B2
  申请人：——

  公开号：US7572923B2

  公开（公告）日：2009-08-11
• [EN] DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'AGONISTES DU RÉCEPTEUR DE L'ARYL-HYDROCARBONE
  申请人：[en]AZORA THERAPEUTICS, INC.

  公开号：WO2023060268A1

  公开（公告）日：2023-04-13

  A compound having one of the following structures of Formula (IV) or (V): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, R4, R5R6, R7, R8, R10, R11aR11b, R12aR12b, X, Y, and Z are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
• Synthesis and structure–activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities
  作者：Myoung Ju Moon、Sang Kook Lee、Jong-Won Lee、Woo Keun Song、Si Wouk Kim、Jae Il Kim、Chunghee Cho、Soo Jeong Choi、Yong-Chul Kim

  DOI：10.1016/j.bmc.2005.08.008

  日期：2006.1

  Indirubin, an active ingredient of a traditional Chinese recipe Danggui Loughui Wan, has been known as it CDK inhibitor competing with ATP for binding to the catalytic site of cyclin-dependent kinases (CDKs). Since CDKs, a group of serine/ threonine kinases forming active heterodimeric complexes with cyclins, are key regulators of the cell cycle regulation, therapeutic interventions targeting CDKs have been stimulated for the treatment of proliferative diseases, such as cancer, psoriasis, and for the prevention of chemotherapy-associated side effects, Such its alopecia. A series of novel indirubin analogs was synthesized and evaluated for anti-proliferative and CDK2 inhibitory activities. Among the indirubin derivatives tested in the growth inhibitions against several human cancer cell lines, 5-nitro, halide, and bulky group Containing acylamino Substituted analogs showed high anti-proliferative effects. Selected analogs showing potent anti-proliferative activities were evaluated further in the CDK2 enzyme assay, Which resulted in the discovery of potent CDK2 inhibitors. (c) 2005 Elsevier Ltd. All rights reserved.